Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs, SOR/2026-162
Section 4
Deeming — joint review involving Minister
Cite as Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs, SOR/2026-162, s. 4 · current to July 21, 2026 · regulation last amended July 15, 2026
Statute Watch
Get an alert when a bill in Parliament would change this section, and every time it moves.
The text
(1) This section does not apply to a manufacturer that seeks a notice of compliance in respect of a new drug submission on the basis of a direct or indirect comparison between the drug that is the subject of the submission and another drug that is authorized to be sold in Canada.
(2) Subject to subsections (3) to (5), the requirement in subsection C.08.004(1) or (3) of the Regulations, as the case may be, that the Minister complete an examination of a new drug submission is deemed to be met, in respect of the drug that is the subject of the submission, on the basis of a document referred to in paragraph (e) produced in the context of a joint review if the following requirements are met:
(a) the drug belongs to a class of drugs that is set out in Division 3 of Part 1 of the List;
(b) the manufacturer indicates to the Minister that it seeks the applicable requirement in section C.08.004 of the Regulations to be deemed to be met under this section in respect of the portion of the following sets of information, included in the submission, that is to be examined by a foreign regulatory authority in the context of the joint review:
(i) the information referred to in paragraphs C.08.002(2)(g), (k) and (m) and C.08.005.1(1)(b) and (c) of the Regulations, to the extent that those paragraphs relate to non-clinical information,
(ii) the information referred to in paragraphs C.08.002(2)(g) to (i), (k) and (m) and C.08.005.1(1)(b) and (c) of the Regulations, to the extent that those paragraphs relate to clinical information, and
(iii) the information referred to in paragraphs C.08.002(2)(a), (c) to (f), (l) and (m) of the Regulations, to the extent that those paragraphs relate to chemistry and manufacturing information;
(c) the Minister conducts the joint review that pertains to the drug and a foreign drug with the foreign regulatory authority;
(d) the foreign regulatory authority is set out in Division 3 of Part 1 of the List in relation to the class of drugs to which the drug belongs;
(e) the Minister has received a copy of the document produced by the foreign regulatory authority in the context of the joint review that sets out the conclusions of its examination of the portion referred to in paragraph (b); and
(f) the manufacturer provides the Minister with information that demonstrates
(i) that the drug has the same strength, dosage form, route of administration and medicinal ingredient as the foreign drug,
(ii) that the conditions of use for the drug fall within the conditions of use for the foreign drug, and
(iii) with respect to the portion referred to in paragraph (b),
(A) any difference between the drug and the foreign drug, and
(B) that any such difference would not — if the Minister were to issue a notice of compliance in respect of the submission — impact the safety or effectiveness of the drug.
(3) The requirement in subsection C.08.004(1) or (3) of the Regulations, as the case may be, that the Minister complete an examination of a new drug submission is deemed to be met under this section only in respect of the portion referred to in paragraph (2)(b) that is addressed by the document referred to in paragraph (2)(e).
(4) Despite subsection (3), the requirement in subsection C.08.004(3) of the Regulations that the Minister complete an examination of a new drug submission is not deemed to be met under this section in respect of the portion referred to in paragraph (2)(b) that is addressed by the document referred to in paragraph (2)(e) if the Minister issued a notice to the manufacturer under paragraph C.08.004(1)(b) of the Regulations based on the document.
(5) Despite subsection (3), the applicable requirement referred to in that subsection is not deemed to be met under this section in respect of information that is related to any difference identified under clause (2)(f)(iii)(A).
Read the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs on the Justice Laws Website ↗
Made under Food and Drugs Act, R.S.C. 1985, c. F-27.
Bills in Parliament that would change this section 0
No bill we hold would amend or repeal this section.